Published in final edited form as:

Biochemistry. 2011 June 7; 50(22): 5058–5066. doi:10.1021/bi200531q.

Contributions of the D-Ring to the Activity of Etoposide Against Human Topoisomerase II α : Potential Interactions with DNA in the Ternary Enzyme-Drug-DNA Complex[†]

Steven L. Pitts[‡], Michael J. Jablonksy[§], Maria Duca^{||,§§}, Daniel Dauzonne^{¶,⊥}, Claude Monneret^{¶,⊥}, Paola B. Arimondo^{||,‡‡}, Clemens Anklin^{¶¶}, David E. Graves^{§,*}, and Neil Oshero^{†,‡,*,*}

Departments of Biochemistry and Medicine (Hematology/Oncology), Vanderbilt University School of Medicine, Nashville, TN 37232-0146 USA, Department of Chemistry, University of Alabama at Birmingham, Birmingham, AL 35294 USA, UMR7196 CNRS, Muséum National d'Histoire Naturelle, INSERM UR565, 75005 Paris, France; Institut Curie, Centre de Recherche, 75248, Paris, France; UMR176 CNRS, Institut Curie Section de Recherche, 75248 Paris, France; and Bruker BioSpin Corporation, Billerica, MA 01821 USA

Abstract

Etoposide is a widely prescribed anticancer drug that stabilizes covalent topoisomerase II-cleaved DNA complexes. The drug contains a polycyclic ring system (rings A–D), a glycosidic moiety at C4, and a pendant ring (E–ring) at C1. Interactions between human topoisomerase II α and etoposide in the binary enzyme-drug complex appear to be mediated by substituents on the A-, B-, and E-rings of etoposide. These protein-drug contacts in the binary complex have predictive value for the actions of etoposide within the ternary topoisomerase II α -drug-DNA complex. Although the D-ring of etoposide does not appear to contact topoisomerase II α in the binary complex, etoposide derivatives with modified D-rings display reduced cytotoxicity against murine leukemia cells [Meresse et al. (2003) *Bioorg. Med. Chem. Lett.*, 13, 4107]. This finding suggests that alterations in the D-ring may affect etoposide activity towards topoisomerase II α in the ternary enzyme-drug-DNA complex. Therefore, to address the potential contributions of the D-ring to the activity of etoposide, drug derivatives in which the C13 carbonyl was moved to the C11 position (retroetoposide and retroDEPT) or the D-ring was opened (D-ring diol) were characterized. All of the D-ring alterations diminished the ability of etoposide to enhance DNA cleavage mediated by human topoisomerase II α in vitro and in cultured cells. They also decreased etoposide binding in the ternary enzyme-drug-DNA complex and altered sites of enzyme-mediated DNA cleavage. Based on these findings, we propose that the D-ring of etoposide has important interactions with DNA in the ternary topoisomerase II cleavage complex.

[†]This work was supported by National Institutes of Health grant GM33944 (NO), Department of Defense grant DOD/CDMRP-BCRP BC095831P1 (DEG), and Ligue Nationale Contre le Cancer and ACI 'Molécules et Cibles Thérapeutiques' du Ministère de la Recherche (PBA).

*Correspondence regarding DNA topoisomerase II should be addressed to Neil Oshero: tel: 615-322-4338. fax: 615-343-1166. neil.osheroff@vanderbilt.edu. *Correspondence regarding NMR should be addressed to David E. Graves: tel: 205-975-5381. fax: 205-975-2543. dgraves@uab.edu.

[‡]Department of Biochemistry, Vanderbilt University School of Medicine

[§]Department of Medicine (Hematology/Oncology), Vanderbilt University School of Medicine

^{||}Department of Chemistry, University of Alabama at Birmingham

[¶]CNRS UMR7196 MNHN INSERM U565

[⊥]Institut Curie, Centre de Recherche

^{¶¶}CNRS UMR176, Institut Curie Section de Recherche

^{¶¶¶}Bruker BioSpin Corporation

^{§§}Present address: CNRS UMR6001, University of Nice, France.

^{‡‡}Present address: CNRS-Pierre Fabre USR3388, Toulouse, France.

Etoposide is a highly successful anticancer agent that has been used to treat a variety of blood-borne and solid human malignancies for nearly thirty years (1–4). The drug is a derivative of podophyllotoxin, a naturally occurring antimitotic agent from May apples (1, 5). Etoposide kills cells by stabilizing covalent topoisomerase II-cleaved DNA complexes that are formed during the DNA strand passage reaction of the enzyme (6–9). These transient “cleavage complexes” are converted to permanent DNA strand breaks by collisions with DNA tracking systems, which generate chromosomal aberrations, destabilize the genome, and trigger cell death pathways (7–12). Because etoposide converts topoisomerase II to a cellular toxin, it is referred to as a topoisomerase II poison (6–9).

Humans encode two closely related isoforms of topoisomerase II, topoisomerase II α and topoisomerase II β (13–16). The individual contributions of these isoforms to the clinical efficacy of etoposide have yet to be determined. However, recent evidence suggests that topoisomerase II α may play a more prominent role in mediating the cytotoxic effects of topoisomerase II-targeted anticancer drugs (17–19). Coupled with the fact that the concentration of topoisomerase II α is generally higher in malignant as compared to corresponding normal tissues, most studies of etoposide action have focused on the α isoform (20–22).

Previous studies indicate that interactions between topoisomerase II and etoposide are critical for drug activity and mediate the entry of etoposide into the ternary enzyme-drug-DNA complex (23–26). Therefore, substituents on etoposide that contact topoisomerase II in the binary enzyme-drug complex have been identified by STD ^1H NMR spectroscopy (25, 26). These substituents include the C15 geminal protons of the A-ring, the C5 and C8 protons of the B-ring, the C2' and C6' protons of the pendant E-ring, and the 3'- and 5'-methoxyl protons of the E-ring (Figure 1). In contrast, no protein contacts have been observed for the C1 and C4 protons of the C-ring, the C2 and C3 protons that bridge the C- and D-rings, the C11 protons of the D-ring, and any protons on the C4 glycosidic moiety. An identical set of drug contacts were seen in a binary complex between topoisomerase II α and DEPT, an etoposide derivative that lacks the C4 glycosidic group (Figure 1).

Protein-drug contacts in the binary complex have predictive value for the actions of etoposide within the ternary topoisomerase II-drug-DNA complex (25, 26). Opening of the A-ring or altering the 3', 4', or 5' substituents of the E-ring dramatically decreases the efficacy of etoposide, but does not affect the specificity of DNA cleavage (25, 26). Thus, it was concluded that etoposide interacts with topoisomerase II through the A-, B-, and E-rings. Conversely, the loss of the C4 glycosidic group in DEPT has relatively little effect on the ability of the drug to enhance topoisomerase II-mediated DNA scission, but does induce subtle changes in cleavage specificity and site utilization (26). Consequently, it has been suggested that the C4 glycoside, along with the D-ring, may mediate interactions with DNA in the cleavage complex (26).

Therefore, to explore potential interactions between the D-ring and DNA during topoisomerase II-mediated DNA cleavage, a series of etoposide derivatives, including retroetoposide, retroDEPT, and the D-ring diol were characterized. Results indicate that D-ring alterations diminish the ability of etoposide to enhance DNA cleavage mediated by human topoisomerase II α in vitro and in cultured human cells. They also decrease etoposide binding in the ternary enzyme-drug-DNA complex and alter sites of enzyme-mediated DNA cleavage. Based on these findings, it is concluded that the D-ring of etoposide has important interactions with DNA in the topoisomerase II cleavage complex.

EXPERIMENTAL PROCEDURES

Materials

Human topoisomerase II α was expressed in *Saccharomyces cerevisiae* and purified as described previously (27, 28). However, in the final step of the purification, topoisomerase II α was eluted from the phosphocellulose column (P81, Whatman) with buffer containing 10 mM sodium phosphate (pH 7.7), 750 mM KCl, 1 mM EDTA, 1 mM EGTA, and 0.5 mM dithiothreitol. For protein samples that were used in NMR experiments, the elution buffer was made up in D₂O (99.9%, Aldrich) instead of H₂O. Negatively supercoiled pBR322 plasmid DNA was prepared using a Plasmid Mega Kit (Qiagen) as described by the manufacturer. Etoposide was purchased from Sigma. Retroetoposide, DEPT, retroDEPT, and the D-ring diol were synthesized as described previously (29). All drugs were stored at 4 °C as 20 mM stock solutions in 100% DMSO. Drugs used for NMR experiments were stored in 100% d-DMSO. All other chemicals were analytical reagent grade.

Cleavage of Plasmid DNA by Human Topoisomerase II α

DNA cleavage reactions were carried out using the procedure of Fortune and Osheroff (30). Unless stated otherwise, assay mixtures contained 150 nM topoisomerase II α and 10 nM negatively supercoiled pBR322 DNA in a total of 20 μ L of cleavage buffer [10 mM Tris-HCl (pH 7.9), 100 mM KCl, 5 mM MgCl₂, 0.1 mM NaEDTA, and 2.5% glycerol] that contained 0 to 200 μ M etoposide, retroetoposide, DEPT, retroDEPT, or D-ring diol. DNA cleavage was initiated by the addition of enzyme and mixtures were incubated for 6 min at 37 °C to establish DNA cleavage-ligation equilibria. Enzyme-DNA cleavage intermediates were trapped by adding 2 μ L of 5% SDS and 1 μ L of 375 mM EDTA (pH 8.0). Proteinase K was added (2 μ L of 0.8 mg/mL) and reactions were incubated for 30 min at 45 °C to digest the topoisomerase II α . Samples were mixed with 2 μ L of 60% sucrose in 10 mM Tris-HCl (pH 7.9), 0.5% bromophenol blue, and 0.5% xylene cyanol FF, heated for 15 min at 45 °C, and subjected to electrophoresis in 1% agarose gels in 40 mM Tris-acetate (pH 8.3), 2 mM EDTA that contained 0.5 μ g/mL ethidium bromide. DNA cleavage was monitored by the conversion of negatively supercoiled plasmids to linear molecules. DNA bands were visualized by ultraviolet light and quantified using an Alpha Innotech digital imaging system.

DNA Ligation

DNA ligation mediated by topoisomerase II α was monitored according to the procedure of Byl et al. (31). Topoisomerase II α DNA cleavage-ligation equilibria were established as described above in the absence of compound or in the presence of 100 μ M etoposide, retroetoposide, DEPT, retroDEPT, or D-ring diol. Ligation was initiated by shifting reaction mixtures from 37 to 0 °C, and reactions were stopped at time points up to 30 s by the addition of 2 μ L of 5% SDS followed by 1 μ L of 375 mM NaEDTA (pH 8.0). Samples were processed and analyzed as described above for plasmid DNA cleavage reactions.

Drug-induced DNA Cleavage Mediated by Topoisomerase II α in Cultured Human CEM Cells

Human CEM acute lymphoblastic leukemia cells (ATCC) were cultured under 5% CO₂ at 37 °C in RPMI 1640 medium (Cellgro by Mediatech, Inc.) containing 10% heat-inactivated fetal calf serum (Hyclone) and 2 mM glutamine (Cellgro by Mediatech, Inc.). The *In vivo* Complex of Enzyme (ICE) bioassay (32, 33) (as modified on the TopoGEN, Inc. website) was employed to determine the ability of 25 μ M etoposide, retroetoposide, DEPT, retroDEPT, or D-ring diol to induce topoisomerase II α -mediated DNA breaks in CEM cells. Exponentially growing cultures were treated with DMSO or drugs for 1 h. Cells ($\sim 5 \times 10^6$) were harvested by centrifugation and lysed by the immediate addition of 3 mL of 1%

sarkosyl. Following gentle dounce homogenization, cell lysates were layered onto a 2 mL cushion of CsCl (1.5 g/mL) and centrifuged in a Beckman NVT 90 rotor at 80,000 rpm ($\sim 500,000 \times g$) for 5.5 h at 20 °C. DNA pellets were isolated, resuspended in 5 mM Tris-HCl (pH 8.0), 0.5 mM EDTA, and blotted onto nitrocellulose membranes using a Schleicher and Schuell slot blot apparatus. Covalent cleavage complexes formed between topoisomerase II α and chromosomal DNA were detected using a polyclonal antibody directed against human topoisomerase II α (Kiamaya Biochemical Co.) at a 1:1000 dilution.

STD ^1H NMR Spectroscopy

NMR spectra were generated using conditions similar to those described previously (25, 26). All NMR experiments were performed at 283 K using a Bruker Avance 700 MHz spectrometer equipped with a 5 mm cryoprobe with z gradients. NMR buffers contained 10 mM sodium phosphate (pH 7.7), 250 mM KCl, 0.1 mM Na₂EDTA, and 5 mM MgCl₂. Samples (400 μL) contained 5 μM human topoisomerase II α and 500 μM etoposide, retroetoposide, DEPT, retroDEPT, or D-ring diol and were maintained at 4 °C until data were collected. STD ^1H NMR experiments employed a pulse scheme similar to that reported by Mayer and Meyer (34). A 2 s saturation pulse was used for the saturation, with on- and off-resonance irradiation frequencies of 0.5 and -71 ppm, respectively. The water signal was suppressed using excitation sculpting with gradients. For each experiment (on- and off-resonance irradiation), 256 scans were collected with a 2 s recycle time. Difference spectra were prepared by subtracting the on-resonance spectrum from the off-resonance spectrum. Signals resulting in the difference spectrum represent the NOE difference signals generated by the transfer of irradiation energy from the enzyme to the bound ligand. Ligand protons in close spatial proximity with the enzyme displayed larger NOE signals. Mapping of the NOE signals with their proton assignments on the ligand revealed the ligand-binding epitope to human topoisomerase II α . Spectra were processed using Bruker Topspin software.

Cleavage Site Utilization in Linear Plasmid DNA

DNA cleavage sites were mapped using a modification (35) of the procedure of O'Reilly and Kreuzer (36). The pBR322 DNA substrate was linearized by treatment with *Hind*III. Terminal 5'-phosphates were removed by treatment with calf intestinal alkaline phosphatase and replaced with [^{32}P]phosphate using T4 polynucleotide kinase and [γ - ^{32}P]ATP. The DNA was treated with *Eco*RI, and the 4332 bp singly-end-labeled fragment was purified from the small *Eco*RI-*Hind*III fragment by passage through a CHROMA SPIN+TE-100 column (Clontech). Reaction mixtures contained 0.7 nM labeled pBR322 DNA and 90 nM human topoisomerase II α in 20 μL of DNA cleavage buffer supplemented with 0.5 mM ATP in the absence of drug or in the presence of 10 μM etoposide, 25 μM DEPT, or 250 μM retroetoposide, retroDEPT, or D-ring diol. Reaction mixtures were incubated for 6 min at 37 °C and enzyme-DNA cleavage complexes were trapped by the addition of 2 μL of 5% SDS followed by 2 μL of 250 mM EDTA (pH 8.0). Proteinase K (2 μL of a 0.8 mg/mL solution) was added, and samples were incubated for 30 min at 45 °C to digest the enzyme. DNA products were ethanol precipitated and resuspended in 6 μL of 40% formamide, 10 mM NaOH, 0.02% xylene cyanol FF, and 0.02% bromophenol blue. Samples were subjected to electrophoresis in denaturing 6% polyacrylamide sequencing gels. Gels were dried in vacuo, and DNA cleavage products were visualized with a Bio-Rad Molecular Imager FX.

Cleavage Site Utilization in Oligonucleotide Substrates

A 47-bp oligonucleotide corresponding to residues 80–126 of pBR322 and its complement were employed to compare the DNA cleavage site specificity of etoposide to that of retroetoposide (37). Oligonucleotide substrates were prepared on an Applied Biosystems DNA synthesizer. The sequences of the top and bottom strands were 5'-CCGTGTATGAAATCTAACAATX↓CGCTCATCGTCATCCTC-GGCACCGT-3' and 5'-

ACGGTGCCGAGGATGACGATG↓AGCGZATTGTTAGATTTCA-TACACGG-3', respectively. This substrate contains a single strong cleavage site for topoisomerase II that has been well characterized (38–40). Points of scission are denoted by arrows. Oligonucleotides were prepared that contained a G (found in the wild-type sequence), C, A, or T at the –1 position on the top strand (denoted by the bold X). Complementary bottom strand oligonucleotides contained a C, G, T, or A, respectively, at the position denoted by the bold Z. Single-stranded oligonucleotides were labeled on their 5'-termini using T4 polynucleotide kinase (New England Biolabs) and [γ - 32 P]ATP (~6000 Ci/mmol, Perkin Elmer LAS). Following labeling and gel purification, complementary oligonucleotides were annealed by incubation at 70°C for 10 min and cooling to 25°C.

DNA cleavage by human topoisomerase II α was determined as described previously (28). Reaction mixtures contained 220 nM human topoisomerase II α and 100 nM double-stranded oligonucleotide in 20 μ L of cleavage buffer containing 0–500 μ M etoposide or retroetoposide. Reactions were incubated for 10 min at 37 °C. DNA cleavage products were trapped by the addition of 2 μ L of 10% SDS, followed by 1 μ L of 375 mM EDTA (pH 8.0). Samples were digested with proteinase K, ethanol precipitated, and resolved by electrophoresis in 7 M urea, 14% polyacrylamide gels in 100 mM Tris–borate (pH 8.3), 2 mM EDTA. DNA cleavage products were visualized and quantified on a Bio-Rad Molecular Imager FX.

RESULTS AND DISCUSSION

Interactions between topoisomerase II and substituents on the A-ring, E-ring, and C4 position of etoposide in the binary enzyme-drug complex (identified by STD 1 H NMR spectroscopy) predict the ability of etoposide to stabilize the covalent topoisomerase II-DNA cleavage complex (25, 26). However, retroetoposide and retroDEPT display reduced cytotoxicity (~8- and 32-fold, respectively, as compared to etoposide) against murine leukemia L1210 (29) despite the fact that NMR studies indicate that none of the protons on the D-ring of etoposide (*i.e.*, the C2, C3 and C11 protons) contact human topoisomerase II α in the binary complex (25, 26). Although differences in drug cytotoxicity may reflect physiological attributes such as uptake or efflux, etc., this finding suggests that alterations in the D-ring of etoposide may affect drug activity towards topoisomerase II α in the ternary enzyme-drug-DNA complex.

Activity of Etoposide D-Ring Derivatives Against Human Topoisomerase II α

To address the role of the D-ring in etoposide function, the effects of retroetoposide, DEPT, retroDEPT, and the D-ring diol (see Figure 1 for structures) on DNA cleavage mediated by human topoisomerase II α were compared to that of etoposide (Figure 2). As reported previously (26), the activity of DEPT was ~80–90% that of the parent compound. In contrast, the ability of retroetoposide, retroDEPT, and the D-ring diol to stimulate enzyme-mediated DNA cleavage was reduced substantially. Levels of DNA scission observed in the presence of retroetoposide were ~2- to 3-fold lower than seen with etoposide. The activity of retroDEPT was similarly reduced as compared to DEPT and was lower than that of retroetoposide. Thus, the effects of the two changes in etoposide to generate retroDEPT (*i.e.*, the loss of the C4 glycoside and the transposition of the C13 ketone to the C11 position) appear to be additive. Finally, the D-ring diol displayed no ability to stimulate DNA cleavage mediated by topoisomerase II α .

The above results suggest that the decreased cytotoxicity of retroetoposide and retroDEPT are due, at least in part, to a decreased activity against topoisomerase II. Together with the findings for the D-ring diol, DNA cleavage results provide strong evidence that substituents

on the D-ring of etoposide can profoundly affect the ability of the drug to act as a topoisomerase II poison.

It has been suggested that the diminished cellular activity of retroetoposide results from a deleterious interaction between the C4 glycoside and the C11 carbonyl group (29). However, since the decreased activity of retroDEPT compared to DEPT was similar to that for retroetoposide compared to etoposide, this explanation seems unlikely.

Etoposide increases levels of cleavage complexes by inhibiting the ability of topoisomerase II to ligate DNA (41, 42). Therefore, the effects of the D-ring derivatives on DNA ligation mediated by topoisomerase II α were determined. As seen in Figure 3 (left panel), all of the compounds displayed a reduced activity compared to etoposide, with the order being the same as seen in DNA cleavage assays (etoposide > DEPT > retroetoposide > retroDEPT >> D-ring diol). Moreover, there was a strong correlation between the ability of the drugs to inhibit ligation and increase levels of DNA cleavage (right panel). These results indicate that the derivatives increase levels of topoisomerase II-mediated strand breaks by the same mechanism as that of the parent compound (*i.e.*, inhibition of DNA ligation).

As discussed above, retroetoposide and retroDEPT are cytotoxic to leukemia cells, but are less potent than etoposide (29). Therefore, to determine whether the reduced cytotoxicity of D-ring derivatives correlates with a decreased activity against topoisomerase II α , we assessed the ability of DEPT, retroetoposide, retroDEPT, and the D-ring diol to induce DNA cleavage by the type II enzyme in cultured human CEM leukemia cells. As seen in Figure 4, drug activity correlated with results of the *in vitro* DNA cleavage assays: DEPT, retroetoposide, and retroDEPT (in that order) induced reduced cellular levels of cleavage complexes compared to etoposide, and the D-ring diol displayed no activity. These findings strongly suggest that the cytotoxicity of retroetoposide and retroDEPT reflects drug activity against topoisomerase II α .

Interactions of Etoposide D-Ring Derivatives with Human Topoisomerase II α

Although the C2, C3, and C11 protons associated with the D-ring of etoposide do not appear to interact with topoisomerase II α in the binary complex (25, 26), alterations in the D-ring profoundly affect the ability of the drug to poison topoisomerase II α *in vitro* and in cultured human cells (Figures 2 and 4). This dichotomy suggests one of two things: either alterations in the D-ring affect contacts between etoposide and the enzyme in the binary complex, or this portion of etoposide has critical interactions in the ternary complex that are not reflected in the absence of DNA. To address these possibilities, interactions between topoisomerase II α and retroetoposide, retroDEPT, and the D-ring diol were identified by STD ^1H NMR spectroscopy.

Off-resonance and difference spectra for samples containing topoisomerase II α and retroetoposide, retroDEPT, and the D-ring diol are shown in Figure 5. Resonances for all visible protons for these drugs, as well as etoposide and DEPT, are given in Table 1.

With the exception of one additional contact with the enzyme (the C4 proton of the C-ring), the substituents on retroetoposide and retroDEPT that interact with human topoisomerase II α in the binary complex were the same as those previously described for etoposide and DEPT (25, 26). However, the nuclear Overhauser enhancement (NOE) signals seen for the E-ring protons of both drugs were substantially broader than found with etoposide in the binary complex. This finding suggests that movement of the C13 carbonyl group to the C11 position may alter the conformation around the E-ring of etoposide and affect interactions between this portion of the drug and the enzyme.

In contrast to retroetoposide and retroDEPT, the substituents on the D-ring diol that contact topoisomerase II α in the binary complex were identical to those of etoposide and no broadening of the E-ring proton resonances were observed. This result indicates that the loss of the D-ring does not alter drug interactions in the binary complex and implies that the lack of DNA cleavage enhancement induced by this derivative results from a specific difference in drug interactions within the ternary complex. Therefore, a competition assay was carried out to address this possibility. As seen in Figure 6, the D-ring diol was unable to displace 50 μ M etoposide from the ternary topoisomerase II α -DNA cleavage complex, even at concentrations that were 10-fold higher than that of the parent compound. Thus, despite the fact that the D-ring diol and etoposide display similar contacts with topoisomerase II α in the binary complex, their interactions in the ternary complex (at least with regard to strength) appear to differ. Because the difference between the binary and ternary complex is the presence of DNA, this finding suggests that the D-ring may have important interactions with the double helix in the covalent topoisomerase II α -drug-DNA cleavage complex.

Effects of D-Ring Substitutions on the Specificity of Topoisomerase II α -mediated DNA Cleavage

A previous study demonstrated that removal of the C4 glycoside alters the specificity of etoposide-induced DNA cleavage by human topoisomerase II α (also shown in Figure 7) (26). Consequently, it was proposed that the sugar moiety of etoposide interacts with DNA in the cleavage complex. Because the etoposide D-ring does not appear to contact topoisomerase II α in the binary complex but modification of this group significantly diminishes drug activity, sites of cleavage were mapped to determine if the D-ring also has the potential to interact with the double helix in the cleavage complex.

As seen in Figure 7, there were substantial differences in the cleavage specificity/site utilization of topoisomerase II α in the presence of etoposide vs. retroetoposide. Similar differences were seen when comparing cleavage maps generated in the presence of DEPT vs. retroDEPT. In addition, opening of the D-ring (D-ring diol) abolished all sites of drug-induced DNA cleavage. These results indicate that the specificity of etoposide-induced DNA cleavage is governed, at least in part, by the D-ring. Furthermore, results are consistent with the hypothesis that the D-ring contacts DNA in the topoisomerase II α cleavage complex. Because movement of the C13 carbonyl to the C11 position appears to affect the conformation of the etoposide E-ring, an alternative hypothesis is that D-ring alterations affect cleavage specificity by indirectly changing protein-drug contacts. However, two findings argue against this latter interpretation. First, the D-ring diol displays no ability to induce topoisomerase II α -mediated DNA cleavage, despite the fact that the protein-drug contacts in the binary complex are the same as those seen with etoposide. Second, a previous study found that derivatization of the etoposide E-ring significantly diminishes levels of drug-induced DNA cleavage, but has no effect on the site specificity of human topoisomerase II α (25).

To further examine the effects of D-ring derivatization on the cleavage specificity of the type II enzyme, the ability of etoposide and retroetoposide to induce topoisomerase II α -mediated DNA cleavage of an oligonucleotide substrate was compared. Etoposide displays specificity for the -1 base relative to the scissile bond and generally prefers to cleave substrates with a C at this position (43, 44). With the oligonucleotide used for cleavage experiments, etoposide preferentially induced cleavage when the substrate contained a -1 C or A (Figure 8). Scission levels dropped ~2-fold when a T or G was present at this position.

Compared to etoposide, retroetoposide displays a decreased specificity for a -1 C or A (Figure 8). In fact, levels of topoisomerase II α -mediated DNA scission with the -1 G

substrate were comparable to those seen in the presence of C or A. This finding confirms that changes in the D-ring of etoposide alter the DNA cleavage specificity of the drug.

Conclusions

Although etoposide is in its fourth decade of clinical use, relationships between drug activity and interactions within the binary topoisomerase II-drug complex and the ternary topoisomerase II-drug-DNA complex have been addressed only recently. Based on the results of STD ¹H NMR spectroscopy and enzyme-drug binding in the binary complex, as well as drug competition and DNA cleavage in the ternary complex, a model has emerged (Figure 9). In this model, the binding of etoposide to human topoisomerase II α is driven by interactions with the A-ring, B-ring, and potentially by stacking interactions with the E-ring (25, 26). The E-ring methoxyl groups and the 4'-OH moiety are important for drug function, but do not contribute substantially to enzyme-drug binding or DNA cleavage specificity (25, 26).

Neither the C4 glycoside nor the D-ring of etoposide contact the enzyme in the binary complex (25, 26). While removal of the sugar has little effect on drug activity, it subtly alters the specificity of DNA cleavage. In contrast, D-ring modifications profoundly affect the ability of etoposide to induce DNA scission and alter the cleavage specificity of topoisomerase II α . Taken together, we propose that interactions between etoposide and DNA in the ternary complex are driven primarily by the D-ring, with additional contributions from the C4 sugar. This hypothesis is supported by recent studies on F14512, an etoposide derivative that replaces the C4 glycoside with a spermine moiety (45–47). The presence of the spermine enhances DNA interactions and increases the potency of the drug against human type II topoisomerases (45–47). Thus, by targeting the C4 moiety and the D-ring, it may be possible to develop novel etoposide derivatives with increased activity and/or altered cleavage specificity.

Acknowledgments

We are grateful to Dr. Amanda C. Gentry, Adam C. Ketron, and Katie J. Aldred for critical reading of the manuscript.

Abbreviations

DEPT	4'-demethyl epipodophyllotoxin;
retroetoposide	11-oxo,13-deoxo-etoposide
retroDEPT	11-oxo,13-deoxo-4'-demethyl epipodophyllotoxin
D-ring diol	11,13-O,O-4'-demethyl epipodophyllotoxin
STD	saturation transfer difference
NOE	nuclear Overhauser enhancement

References

1. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. *Eur J Cancer*. 1998; 34:1514–1521. [PubMed: 9893622]
2. Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. *Biochim Biophys Acta*. 1998; 1400:173–184. [PubMed: 9748560]
3. Holden JA. DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic. *Curr Med Chem Anticancer Agents*. 2001; 1:1–25. [PubMed: 12678768]

4. Baldwin EL, Osheroff N. Etoposide, topoisomerase II and cancer. *Curr Med Chem Anti-Canc Agents*. 2005; 5:363–372.
5. Nitiss JL, Liu YX, Hsiung Y. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. *Cancer Res*. 1993; 53:89–93. [PubMed: 8380128]
6. Pommier Y, Marchand C. Interfacial inhibitors of protein-nucleic acid interactions. *Curr Med Chem Anti-Cancer Agents*. 2005; 5:421–429.
7. McClendon AK, Osheroff N. DNA topoisomerase II, genotoxicity and cancer. *Mut Res*. 2007; 623:83–97. [PubMed: 17681352]
8. Deweese JE, Osheroff N. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. *Nucleic Acids Res*. 2009; 37:738–748. [PubMed: 19042970]
9. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. *Nat Rev Cancer*. 2009; 9:338–350. [PubMed: 19377506]
10. Baguley BC, Ferguson LR. Mutagenic properties of topoisomerase-targeted drugs. *Biochim Biophys Acta*. 1998; 1400:213–222. [PubMed: 9748584]
11. Kaufmann SH. Cell death induced by topoisomerase-targeted drugs: more questions than answers. *Biochim Biophys Acta*. 1998; 1400:195–211. [PubMed: 9748575]
12. Sordet O, Khan QA, Kohn KW, Pommier Y. Apoptosis induced by topoisomerase inhibitors. *Curr Med Chem Anti-Cancer Agents*. 2003; 3:271–290.
13. Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Mattern MR, Johnson RK, Crooke ST. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. *J Biol Chem*. 1987; 262:16739–16747. [PubMed: 2824504]
14. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. *Biochemistry*. 1989; 28:8154–8160. [PubMed: 2557897]
15. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. *Annu Rev Biochem*. 2001; 70:369–413. [PubMed: 11395412]
16. Velez-Cruz, R.; Osheroff, N. DNA topoisomerases: type II. In: Lennarz, W.; Lane, MD., editors. *Encyc Biol Chem*. Vol. I. Elsevier Science Inc; San Diego: 2004. p. 806-811.
17. Sehested M, Holm B, Jensen PB. Dexrazoxane for protection against cardiotoxic effects of anthracyclines. *J Clin Oncol*. 1996; 14:2884. [PubMed: 8874349]
18. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, Liu LF. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. *Proc Natl Acad Sci USA*. 2007; 104:11014–11019. [PubMed: 17578914]
19. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF. Topoisomerase II β mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. *Cancer Res*. 2007; 67:8839–8846. [PubMed: 17875725]
20. Keith WN, Tan KB, Brown R. Amplification of the topoisomerase II alpha gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II α and β loci in normal tissue. *Genes, Chromosomes & Cancer*. 1992; 4:169–175. [PubMed: 1373318]
21. Keith WN, Douglas F, Wishart GC, McCallum HM, George WD, Kaye SB, Brown R. Co-amplification of erbB2, topoisomerase II α and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. *Eur J Cancer*. 1993; 10:1469–1475. [PubMed: 8104440]
22. Skotheim RI, Kallioniemi A, Bjerkhagen B, Mertens F, Brekke HR, Monni O, Mousses S, Mandahl N, Soeter G, Nesland JM, Smeland S, Kallioniemi OP, Lothe RA. Topoisomerase II α is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. *J Clin Oncol*. 2003; 21:4586–4591. [PubMed: 14673046]
23. Burden DA, Kingma PS, Froelich-Ammon SJ, Bjornsti MA, Patchan MW, Thompson RB, Osheroff N. Topoisomerase II-etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. *J Biol Chem*. 1996; 271:29238–29244. [PubMed: 8910583]

24. Kingma PS, Burden DA, Osheroff N. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance. *Biochemistry*. 1999; 38:3457–3461. [PubMed: 10090731]
25. Wilstermann AM, Bender RP, Godfrey M, Choi S, Anklin C, Berkowitz DB, Osheroff N, Graves DE. Topoisomerase II-drug interaction domains: identification of substituents on etoposide that interact with the enzyme. *Biochemistry*. 2007; 46:8217–8225. [PubMed: 17580961]
26. Bender RP, Jablonksy MJ, Shadid M, Romaine I, Dunlap N, Anklin C, Graves DE, Osheroff N. Substituents on etoposide that interact with human topoisomerase II α in the binary enzyme-drug complex: contributions to etoposide binding and activity. *Biochemistry*. 2008; 47:4501–4509. [PubMed: 18355043]
27. Worland ST, Wang JC. Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast *Saccharomyces cerevisiae*. *J Biol Chem*. 1989; 264:4412–4416. [PubMed: 2538443]
28. Kingma PS, Greider CA, Osheroff N. Spontaneous DNA lesions poison human topoisomerase II α and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. *Biochemistry*. 1997; 36:5934–5939. [PubMed: 9166762]
29. Meresse P, Magiatis P, Bertounesque E, Monneret C. Synthesis and antiproliferative activity of retroetoposide. *Bioorg Med Chem Lett*. 2003; 13:4107–4109. [PubMed: 14592517]
30. Fortune JM, Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase II α by blocking DNA cleavage. *J Biol Chem*. 1998; 273:17643–17650. [PubMed: 9651360]
31. Byl JA, Fortune JM, Burden DA, Nitiss JL, Utsugi T, Yamada Y, Osheroff N. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. *Biochemistry*. 1999; 38:15573–15579. [PubMed: 10569941]
32. Subramanian D, Kraut E, Staubus A, Young DC, Muller MT. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. *Cancer Res*. 1995; 55:2097–2103. [PubMed: 7743509]
33. Byl JA, Cline SD, Utsugi T, Kobunai T, Yamada Y, Osheroff N. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. *Biochemistry*. 2001; 40:712–718. [PubMed: 11170388]
34. Mayer M, Meyer B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. *J Am Chem Soc*. 2001; 123:6108–6117. [PubMed: 11414845]
35. Baldwin EL, Byl JA, Osheroff N. Cobalt enhances DNA cleavage mediated by human topoisomerase II α in vitro and in cultured cells. *Biochemistry*. 2004; 43:728–735. [PubMed: 14730977]
36. O'Reilly EK, Kreuzer KN. A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents. *Biochemistry*. 2002; 41:7989–7997. [PubMed: 12069589]
37. Bromberg KD, Burgin AB, Osheroff N. A two-drug model for etoposide action against human topoisomerase II α . *J Biol Chem*. 2003; 278:7406–7412. [PubMed: 12473657]
38. Sander M, Hsieh T. Double strand DNA cleavage by type II DNA topoisomerase from *Drosophila melanogaster*. *J Biol Chem*. 1983; 258:8421–8428. [PubMed: 6305984]
39. Corbett AH, Zechiedrich EL, Osheroff N. A role for the passage helix in the DNA cleavage reaction of eukaryotic topoisomerase II. A two-site model for enzyme-mediated DNA cleavage. *J Biol Chem*. 1992; 267:683–686. [PubMed: 1309770]
40. Kingma PS, Osheroff N. Apurinic sites are position-specific topoisomerase II-poisons. *J Biol Chem*. 1997; 272:1148–1155. [PubMed: 8995415]
41. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. *Biochemistry*. 1989; 28:6157–6160. [PubMed: 2551366]
42. Robinson MJ, Osheroff N. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II. *Biochemistry*. 1991; 30:1807–1813. [PubMed: 1847075]

43. Pommier Y, Capranico G, Orr A, Kohn KW. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. *Nucleic Acids Res.* 1991; 19:5973–5980. [PubMed: 1658748]
44. Capranico G, Binaschi M. DNA sequence selectivity of topoisomerases and topoisomerase poisons. *Biochim Biophys Acta.* 1998; 1400:185–194. [PubMed: 9748568]
45. Barret JM, Kruczynski A, Vispe S, Annereau JP, Brel V, Guminski Y, Delcros JG, Lansiaux A, Guilbaud N, Imbert T, Bailly C. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. *Cancer Res.* 2008; 68:9845–9853. [PubMed: 19047165]
46. Kruczynski A, Vandenberghe I, Pillon A, Pesnel S, Goetsch L, Barret JM, Guminski Y, Le Pape A, Imbert T, Bailly C, Guilbaud N. Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system. *Invest New Drugs.* 2011; 29:9–21. [PubMed: 19777159]
47. Gentry AC, Pitts SL, Jablonsky MJ, Bailly C, Graves DE, Osheroff N. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. *Biochemistry.* 2011 in press (epub 3/17/2011).

Figure 1.
Structures of etoposide, retroetoposide, DEPT, retroDEPT and the D-ring diol.

Figure 2.

Effects of etoposide derivatives on DNA cleavage mediated by human topoisomerase II α . Levels of double-stranded DNA cleavage were expressed as a fold-enhancement over reactions that were carried out in the absence of drug. Assay mixtures contained 0–200 μ M etoposide (closed circles), DEPT (closed squares), retroetoposide (rEtop, open circles), retroDEPT (rDEPT, open squares), or D-ring diol (open triangles). Error bars represent the standard deviation of three independent experiments.

Figure 3.

Left: DNA ligation was examined in the absence of compound (no drug, closed triangles) or in the presence of 100 μ M etoposide (closed circles), DEPT (closed squares), retroetoposide (rEtop, open circles), retroDEPT (rDEPT, open squares), or D-ring diol (open triangles). Right: Comparison of DNA cleavage (closed bars, 100 μ M drug) and ligation (open bars, 30 s) mediated by human topoisomerase II α in the presence of etoposide (E), DEPT (D), retroetoposide (rE), retroDEPT (rD), or D-ring diol (DRD). Error bars represent the standard deviation of three independent experiments.

Figure 4.

Levels of topoisomerase II α -DNA cleavage complexes formed in human CEM leukemia cells that were treated with etoposide derivatives. DNA samples (10 μ g) from cultures treated with no drug (ND) or 25 μ M etoposide (E), DEPT (D), retroetoposide (rE), retroDEPT (rD), or D-ring diol (DRD) for 1 h were blotted onto a nitrocellulose membrane and probed with a polyclonal antibody directed against human topoisomerase II α . Error bars represent the standard deviation of three independent experiments. A representative blot is shown above.

Figure 5. Interaction of retroetoposide (top), retroDEPT (middle), and D-ring diol (bottom) with human topoisomerase II α as determined by STD ^1H NMR spectroscopy. Difference and reference (off resonance) spectra are shown for each drug. Spectra are representative of at least two independent experiments.

Figure 6. Competition between the D-ring diol and etoposide in the ternary complex. Topoisomerase II α -mediated DNA cleavage in the presence of 50 μ M etoposide and increasing concentrations (up to 500 μ M) of D-ring diol is shown as fold-enhancement over etoposide alone. Error bars represent the standard deviation of three independent experiments.

Figure 7.

DNA cleavage site specificity and utilization by human topoisomerase II α in the presence of etoposide derivatives. A singly end-labeled linear 4332 bp fragment of pBR322 was used as the cleavage substrate. An autoradiogram of a polyacrylamide gel is shown. DNA cleavage reactions contained topoisomerase II α with no drug (Topo), 10 μ M etoposide (Etop), 250 μ M retroetoposide (rEtop), 25 μ M DEPT (DEPT), 250 μ M retroDEPT (rDEPT), or 250 μ M D-ring diol (DRD). A DNA control (DNA) also is shown. Data are representative of four independent experiments.

Figure 8.

Oligonucleotide sequence specificity of etoposide (closed circles) versus retroetoposide (open circles). Drug titrations were performed using an oligonucleotide substrate that contained a strong cleavage site for human topoisomerase II α . The oligonucleotide was synthesized with either a C, A, T, or G at the -1 position relative to the scissile bond. The inset in the lower right panel compares DNA cleavage levels induced by 250 μM etoposide (closed bars) or retroetoposide (open bars) relative to cleavage of the oligonucleotide containing a C at the -1 position, which was set at 1 for both drugs. Error bars represent the standard deviation of three independent experiments.

Figure 9.

Summary of etoposide substituents that interact with human topoisomerase II α . Protons that interact with the enzyme (as determined by STD ^1H NMR spectroscopy) are shown in red (25, 26). Interactions between hydroxyl protons and the enzyme were obscured by the water peak and could not be visualized. The blue region on etoposide, including portions of the A-, B- and E-rings, is proposed to interact with topoisomerase II α in the binary drug-enzyme complex. E-ring substituents highlighted with yellow boxes are important for drug function and interact with the enzyme, but do not appear to contribute significantly to binding (25, 26). We propose that interactions between etoposide and DNA in the ternary complex (shaded in gray) are driven primarily by the D-ring, with additional contributions from the C4 sugar.

Table 1

Drug Substituents that Interact with Human Topoisomerase II α in the Binary Enzyme-Drug Complex as Determined by STD ^1H NMR Spectroscopy^a

Etoposide		Retrotoposide		DEPT		RetroDEPT		D-Ring Diol	
Substituent	Resonance	Substituent	Resonance	Substituent	Resonance	Substituent	Resonance	Substituent	Resonance
1	4.39	1	4.31	1	4.38	1	4.26	1	4.28
2	3.33	2	3.21	2	3.10	2	3.21	2	2.50
3	2.83	3	2.88	3	2.81	3	2.76	3	2.5
4	4.82	4	<u>5.07</u>	4	4.77	4	<u>4.84</u>	4	4.59
<u>5</u>	<u>6.70</u>	<u>5</u>	<u>6.75</u>	<u>5</u>	<u>6.70</u>	<u>5</u>	<u>6.70</u>	<u>5</u>	<u>6.53</u>
<u>8</u>	<u>6.32</u>	<u>8</u>	<u>6.33</u>	<u>8</u>	<u>6.28</u>	<u>8</u>	<u>6.30</u>	<u>8</u>	<u>6.32</u>
11R, 11S	4.15, 4.20	13R, 13S	3.34, 4.34	11R, 11S	4.09, 4.25	13R, 13S	3.45, 4.32		
<u>15R, 15S</u>	<u>5.70</u>	<u>15R, 15S</u>	<u>5.73</u>	<u>15R, 15S</u>	<u>5.67</u>	<u>15R, 15S</u>	<u>5.68</u>	<u>15R, 15S</u>	<u>5.66</u>
<u>2', 6'</u>	<u>6.18</u>	<u>2', 6'</u>	<u>6.15^b</u>	<u>2', 6'</u>	<u>6.11</u>	<u>2', 6'</u>	<u>6.07^b</u>	<u>2', 6'</u>	<u>6.26</u>
<u>3', 5'-OCH₃</u>	<u>3.49</u>	<u>3', 5'-OCH₃</u>	<u>3.49^b</u>	<u>3', 5'-OCH₃</u>	<u>3.45</u>	<u>3', 5'-OCH₃</u>	<u>3.50^b</u>	<u>3', 5'-OCH₃</u>	<u>3.54</u>
1"	4.43	3"	4.44					11-CH ₂	3.44, 3.65
2"	3.07	5"	3.00					13-CH ₂	3.35, 3.53
3"	3.33	6"	3.37						
4"	3.17	7"	3.17						
5"	3.24	9", 12"	3.08						
6", 6"	3.42, 4.01	10", 11"	3.40, 3.97						
7"	4.70	14", 16"	4.64						
-CH ₃	1.10	15"	1.10						

^aResonances that display nuclear Overhauser effects in STD ^1H NMR spectroscopy experiments along with the substituent protons that they represent are indicated in bold and are underlined.

^bIndicated resonances were substantially broadened.